Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

442 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
Fujimoto D, Shibaki R, Kimura K, Haratani K, Tamiya M, Kijima T, Sato Y, Hata A, Yokoyama T, Taniguchi Y, Uchida J, Tanaka H, Furuya N, Miura S, Onishi MI, Sakata S, Miyauchi E, Yamamoto N, Koh Y, Akamatsu H. Fujimoto D, et al. Among authors: furuya n. Lung Cancer. 2025 Jan 2;199:108079. doi: 10.1016/j.lungcan.2024.108079. Online ahead of print. Lung Cancer. 2025. PMID: 39787635
Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529).
Tokito T, Yamada K, Ishii H, Takiguchi Y, Saito G, Minato K, Imai H, Tanaka H, Miura S, Watanabe K, Koreeda Y, Ono A, Furuya N, Misumi T, Hayakawa K, Ogo E, Okamoto H. Tokito T, et al. Among authors: furuya n. Radiat Oncol. 2025 Jan 4;20(1):2. doi: 10.1186/s13014-024-02577-5. Radiat Oncol. 2025. PMID: 39755666 Free PMC article. Clinical Trial.
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H. Sugisaka J, et al. Among authors: furuya n. Lung Cancer. 2024 Dec 9;199:108056. doi: 10.1016/j.lungcan.2024.108056. Online ahead of print. Lung Cancer. 2024. PMID: 39674045
YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: furuya n. Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-1762. Online ahead of print. Clin Cancer Res. 2024. PMID: 39495173
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with NSCLC with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs Chemoimmunotherapy: A Multicenter, Retrospective Study.
Nishioka N, Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K. Nishioka N, et al. Among authors: furuya n. Cancer Res Treat. 2024 Oct 25. doi: 10.4143/crt.2024.748. Online ahead of print. Cancer Res Treat. 2024. PMID: 39482992 Free article.
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib.
Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Umemura S, et al. Among authors: furuya n. J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378-5. doi: 10.1016/j.jtho.2024.10.004. Online ahead of print. J Thorac Oncol. 2024. PMID: 39395663
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
Miura K, Shukuya T, Furuya N, Morita R, Kisohara A, Mouri A, Watanabe S, Tanaka H, Hirata A, Hakozaki T, Hamai K, Matsumoto N, Watanabe K, Ashinuma H, Miyauchi E, Sugano K, Hosokawa S, Amano K, Morita S, Kobayashi K, Maemonodo M, Takahashi K. Miura K, et al. Among authors: furuya n. J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2618-2628. doi: 10.1002/jcsm.13606. Epub 2024 Oct 1. J Cachexia Sarcopenia Muscle. 2024. PMID: 39351653 Free PMC article.
442 results